STDs

For the three months ended June 30, the point-of-care infectious disease diagnostics firm posted $4.1 million in total revenues, up from $3.3 million in Q2 2016.

The foundation will provide funding of no more than $20 million over the four-year term of the deal, and no more than $6 million each year. 

The agency cleared a handful of assays last month for the detection and diagnoses of toxoplasmosis, syphilis, sepsis, thyroid conditions, and other ailments. 

A total of 66 projects were awarded the funding as part of the Biomedical Catalyst 2016 funding. 

As SpeeDx preps for the European launch of its STI tests, it will incorporate UgenTec's automated data analysis tool for PCR applications.

The firm is launching the test for bacterial vaginosis in Europe, the Middle East, and North Africa. 

The US Preventive Services Task Force said that the potential harms resulting from screening for HSV outweigh the potential benefits.